C4 Therapeutics启动Cemsidomide联合地塞米松治疗复发/难治性多发性骨髓瘤的II期Momentum试验首例患者给药

美股速递
Feb 23

C4 Therapeutics公司宣布,其口服IKZF1/3降解剂Cemsidomide联合地塞米松治疗复发/难治性多发性骨髓瘤的II期Momentum临床试验已完成首例患者给药。这一进展标志着该创新疗法在临床开发中迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10